L. Pierre, . Physiologie, . Orthopédie, L. Maintien-À-domicile-isabelle, L. Pharmacologie-cardiovasculaire-dominique et al., Chimie physique générale, Chimie thérapeutique Bertrand RIHN .................................. Biochimie

B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle et al., Chimie thérapeutique Chimie thérapeutique

B. Ariane, B. Cédric, C. Jean-claude, C. Chimie-générale-et-minérale-igor, C. Chimie-analytique-joël et al., Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique

J. Olivier, . Toxicologie, K. Sécurité-sanitaire-francine, L. Pharmacie-galénique-alexandrine, B. Informatique et al., Chimie organique Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique 2) Clinique de la, Biochimie et Biologie Rhinoconjonctivite allergique, p.14

L. , P. La-cavité-nasale, .. La-muqueuse-nasale, and .. , 14 2.1.1.1), p.14

C. , .. La-conjonctive-normale, and .. , 18 2.2.1), 18 2.2.2) Les conjonctivites allergiques saisonnières et perannuelles

.. Qualité-de-vie-de-l-'allergique, ) Comment mesurer l'altération de la qualité de vie ?, p.28

A. Production-des, 36 4.3.1) principe de production, p.38

.. Efficacité-de-l-'omalizumab-dans-la-cascade-réactionnelle-allergique and .. Sur-la-reponse-nasale-aigue, ) Efficacité sur l'inflammation allergique, p.68

J. Baraniuk, Pathogenesis of allergic rhinitis????????????, Journal of Allergy and Clinical Immunology, vol.99, issue.2, pp.763-772, 1997.
DOI : 10.1016/S0091-6749(97)70125-8

S. Romagnani, Immunologic influences on allergy and the TH1/TH2 balance, Journal of Allergy and Clinical Immunology, vol.113, issue.3, pp.395-400, 2004.
DOI : 10.1016/j.jaci.2003.11.025

D. Broide, Molecular and cellular mechanisms of allergic disease?????????, Journal of Allergy and Clinical Immunology, vol.108, issue.2, pp.65-71, 2001.
DOI : 10.1067/mai.2001.116436

C. Owen and E. Immunoglobulin, Immunoglobulin E: Role in asthma and allergic disease: Lessons from the clinic, Pharmacology & Therapeutics, vol.113, issue.1, pp.121-154, 2007.
DOI : 10.1016/j.pharmthera.2006.07.003

M. Dykewicz and R. , 7. Rhinitis and sinusitis, Journal of Allergy and Clinical Immunology, vol.111, issue.2, pp.520-529, 2003.
DOI : 10.1067/mai.2003.82

J. Bousquet, P. Van-cauwenberge, and N. Khaltaev, Allergic Rhinitis and Its Impact on Asthma, Journal of Allergy and Clinical Immunology, vol.108, issue.5, pp.147-334, 2001.
DOI : 10.1067/mai.2001.118891

URL : https://hal.archives-ouvertes.fr/inserm-00815533

S. Ono and M. Abelson, Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment, Journal of Allergy and Clinical Immunology, vol.115, issue.1, pp.118-140, 2005.
DOI : 10.1016/j.jaci.2004.10.042

J. Grossman, One Airway, One Disease, Chest, vol.111, issue.2, pp.11-16, 1997.
DOI : 10.1378/chest.111.2_Supplement.11S

R. Beasley, The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee, Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC Lancet, pp.1225-1257, 1998.

J. Bousquet, F. Neukirch, P. Bousquet, P. Gehano, J. Klossek et al., Severity and impairment of allergic rhinitis in patients consulting in primary care, Journal of Allergy and Clinical Immunology, vol.117, issue.1, pp.158-62, 2006.
DOI : 10.1016/j.jaci.2005.09.047

T. Craig, J. Mccann, F. Gurevich, and M. Davies, The correlation between allergic rhinitis and sleep disturbance, Journal of Allergy and Clinical Immunology, vol.114, pp.139-145, 2004.
DOI : 10.1016/j.jaci.2004.08.044

E. Juniper, T. Rohrbaugh, and E. Meltzer, A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis, Journal of Allergy and Clinical Immunology, vol.111, issue.3, pp.484-490, 2003.
DOI : 10.1067/mai.2003.137

D. Malone, K. Lawson, D. Smith, H. Arrighi, and C. Battista, A cost of illness study of allergic rhinitis in the United States, Journal of Allergy and Clinical Immunology, vol.99, issue.1, pp.22-27, 1997.
DOI : 10.1016/S0091-6749(97)70296-3

C. Desgranges, Anticorps monoclonaux et thérapeutiques Pathologie biologie, pp.351-64, 2004.
DOI : 10.1016/j.patbio.2003.09.017

O. Maurion, Les anticorps monoclonaux à usage thérapeutique : de la conception aux indications

P. Taramcaraz and C. Hauser, L'omalizumab : un nouvel anti IgE pour le traitement de l'asthme sévère, Forum Med Suisse, vol.8, pp.191-195, 2008.

S. Dodig, D. Richter, I. Cepelak, and B. Benko, Anti-IgE therapy with omalizumab in asthma and allergic rhinitis Acta pharmaceutica, pp.123-138, 2005.

L. Presta, R. Shields, O. Connell, L. Lahr, S. Porter et al., The binding site on human immunoglobulin E for its high affinity receptor, J Biol Chem, vol.269, pp.26368-26373, 1994.

P. Belliveau and . Omalizumab, A monoclonal anti-IgE antibody MedGenMed, p.27, 2005.

L. Presta, S. Lahr, R. Shields, J. Porter, C. Gorman et al., Humanization of an antibody directed against IgE, J immunol, vol.151, pp.2623-2632, 1993.

N. Hayashi, Y. Tsukamoto, W. Sallas, and P. Lowe, A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab, British Journal of Clinical Pharmacology, vol.15, issue.5, pp.548-561, 2007.
DOI : 10.1007/BF00173275

K. Verbruggen, P. Van-cauwenberge, and C. Bachert, Anti-IgE for the Treatment of Allergic Rhinitis – and Eventually Nasal Polyps?, International Archives of Allergy and Immunology, vol.148, issue.2, pp.87-98, 2009.
DOI : 10.1159/000155739

T. Casale, I. Berstein, W. Busse, C. Laforce, D. Tinkelman et al., Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis??????????????????, Journal of Allergy and Clinical Immunology, vol.100, issue.1, pp.110-121, 1997.
DOI : 10.1016/S0091-6749(97)70202-1

J. Liu, P. Lester, S. Builder, and S. Shire, Characterization of Complex Formation by Humanized Anti-IgE Monoclonal Antibody and Monoclonal Human IgE, Biochemistry, vol.34, issue.33, pp.635-642, 1995.
DOI : 10.1021/bi00033a020

H. Lin, K. Boesel, D. Griffith, C. Prussin, B. Foster et al., Omalizumab rapidly decreases nasal allergic response and Fc??RI on basophils???, Journal of Allergy and Clinical Immunology, vol.113, issue.2, pp.297-302, 2004.
DOI : 10.1016/j.jaci.2003.11.044

L. Beck, G. Marcotte, D. Macglashan, A. Togias, and S. Saini, Omalizumab-induced reductions in mast cell Fc??RI expression and function, Journal of Allergy and Clinical Immunology, vol.114, issue.3, pp.527-530, 2004.
DOI : 10.1016/j.jaci.2004.06.032

T. Chang and Y. Shiung, Anti-IgE as a mast cell???stabilizing therapeutic agent, Journal of Allergy and Clinical Immunology, vol.117, issue.6, pp.1203-1212, 2006.
DOI : 10.1016/j.jaci.2006.04.005

C. Prussin, D. Griffith, K. Boesel, H. Lin, B. Foster et al., Omalizumab treatment downregulates dendritic cell Fc??RI expression, Journal of Allergy and Clinical Immunology, vol.112, issue.6, pp.1147-1154, 2003.
DOI : 10.1016/j.jaci.2003.10.003

S. Seshi, P. Roller, J. Willette-brown, and J. Kinet, A conformational rearrangement upon binding og IgE to its high affinity receptor, J Biol Chem, vol.271, pp.19256-19263, 1996.

T. Rambasek and M. Kavuru, Omalizumab dosing via the recommended card versus use of the published formula, Journal of Allergy and Clinical Immunology, vol.117, issue.3, pp.708-709, 2006.
DOI : 10.1016/j.jaci.2005.11.042

T. Rambasek, D. Lang, and M. Kavuru, Omalizumab: where does it fit into current asthma management?, Cleveland Clinic Journal of Medicine, vol.71, issue.3, pp.251-261, 2004.
DOI : 10.3949/ccjm.71.3.251

E. Ädelroth, S. Rak, T. Haahtela, G. Aasand, L. Rosenhall et al., Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen???induced seasonal allergic rhinitis, Journal of Allergy and Clinical Immunology, vol.106, issue.2, pp.253-259, 2000.
DOI : 10.1067/mai.2000.108310

T. Casale, J. Condemi, C. Laforce, A. Nayak, M. Rowe et al., Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis, a randomized controlled trial JAMA, pp.2956-2967, 2001.

P. Chervinsky, T. Casale, R. Townley, I. Tripathy, S. Hedgecock et al., Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis, Annals of Allergy, Asthma & Immunology, vol.91, issue.2, pp.160-167, 2003.
DOI : 10.1016/S1081-1206(10)62171-0

G. Hanf, O. Noga, O. Connor, A. Kunkel, and G. , Omalizumab inhibits allergen challenge-induced nasal response, European Respiratory Journal, vol.23, issue.3, pp.414-418, 2004.
DOI : 10.1183/09031936.04.00024504

URL : http://erj.ersjournals.com/content/erj/23/3/414.full.pdf

H. Plewako, M. Arvidsson, K. Petruson, I. Oancea, K. Holmberg et al., The effect of omalizumab on nasal allergic inflammation, Journal of Allergy and Clinical Immunology, vol.110, issue.1, pp.68-71, 2002.
DOI : 10.1067/mai.2002.125488

T. Casale, W. Busse, J. Kline, Z. Ballas, M. Moss et al., Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis, Journal of Allergy and Clinical Immunology, vol.117, issue.1, pp.134-140, 2006.
DOI : 10.1016/j.jaci.2005.09.036

J. Corren, G. Shapiro, J. Reimann, Y. Deniz, D. Wong et al., Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy, Journal of Allergy and Clinical Immunology, vol.121, issue.2, pp.506-511, 2008.
DOI : 10.1016/j.jaci.2007.11.026

M. Humbert, L. Boulet, R. Niven, Z. Panahloo, M. Blogg et al., Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis, Allergy, vol.63, issue.1, pp.81-84, 2009.
DOI : 10.1164/ajrccm/147.4.832

Y. Deniz and N. Gupta, Safety and Tolerability of Omalizumab (Xolair<SUP>??</SUP>), a Recombinant Humanized Monoclonal Anti-IgE Antibody, Clinical Reviews in Allergy & Immunology, vol.29, issue.1, pp.31-48, 2005.
DOI : 10.1385/CRIAI:29:1:031

J. Corren, T. Casale, B. Lanier, R. Buhl, S. Holgate et al., Safety and tolerability of omalizumab, Clinical & Experimental Allergy, vol.39, issue.6, pp.788-97, 2009.
DOI : 10.1111/j.1365-2222.2009.03214.x

D. Vidal, P. Brown, R. Turk, F. Dale, P. Bousquet et al., Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Allergy, pp.149-53, 2007.

A. Wu, A. Paltiel, K. Kuntz, S. Weiss, and A. Fuhlbrigge, Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model, Journal of Allergy and Clinical Immunology, vol.120, issue.5, pp.1146-52, 2007.
DOI : 10.1016/j.jaci.2007.07.055

Y. Oba and G. Salzman, Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma, Journal of Allergy and Clinical Immunology, vol.114, issue.2, pp.265-269, 2004.
DOI : 10.1016/j.jaci.2004.05.049